At a median follow-up of 60.9 months, median EFS was 74.1 months in the pembrolizumab arm and not reached in the placebo arm.
|Videos|December 23, 2022
Dr. Butler discusses 2022 milestones and future anticipations for gender-affirming care
Author(s)Urology Times staff
"We're trying to figure out how to improve people's relationships with their genitals and like their sexual practices," says Christi Butler, MD.
Advertisement
Urology Times® is wrapping up the year by diving into some highlights from different urologic specialties. In this iteration, Christi Butler, MD, discusses her practice in gender-affirming care and gives insight as to what might be on the horizon for the field in 2023. Butler is a urologic surgeon at the University of California, San Francisco.
Advertisement
Related to this article
The phase 1/2 CELC-G-201 study found preliminary antitumor activity and manageable toxicity with gedatolisib plus darolutamide in metastatic castration-resistant prostate cancer.
Kim Chi, MD, FRCPC, discusses the rationale and design of the phase 3 KLK2-comPAS trial evaluating pasritamig alone and in combination with JNJ-9401 in patients with mCRPC.
Longer-term findings from the phase 2 ARACOG study suggest differences in objectively measured cognitive function between ARPIs.
Engy Habashy, MD, discusses key takeaways from the 2025 AUA GSM guideline, including the role of androgens and hormonal therapies in managing genitourinary syndrome of menopause.
Chad R. Ritch, MD, MBA, FACS, discusses how PSMA-PET informs staging, treatment planning, recurrence workup, and the interpretation of equivocal findings.
Michael S. Cookson, MD, MMHC, FACS, discusses how Anktiva’s expanded FDA approval may broaden bladder-preserving treatment options for BCG-unresponsive papillary-only NMIBC.
Jeffrey M. Spier, MD, discusses how fatigue may impact patient quality-of-life and when dose reduction may be an appropriate treatment strategy.
Advertisement
Advertisement
Trending on Urology Times
1
ESMO 2026: Key presentations across genitourinary oncology
2
Darolutamide associated with less cognitive change than enzalutamide in prostate cancer
3
How PSMA-PET shapes staging and recurrence workup in prostate cancer
4
European Commission approves perioperative pembrolizumab plus enfortumab vedotin for MIBC
5